Mabwell Bioscience Soars on Shanghai Exchange Following $571M Deal with Google-Backed Calico for IL-11 Targeting Therapy

June 26, Calico, a life sciences subsidiary of Alphabet under Google Holding, has finalized a biopharmaceutical deal worth up to $571 million, with the aim ofAcquire Rights Related to IL-11 Targeted Therapy in Mabwell Bioscience's Research. This transaction includes a clinical-stage monoclonal antibody (mAb) targeting age-related diseases.

On June 27 (today), Mabwell directly hit the upper limit in A-share.

• In addition toCalico's transaction, on the same day,Mabwell alsoAuthorize itThe Greater China rights for the new generation of long-acting G-CSF (leukocyte booster) Pegfilgrastim α for injection (brand name: Milestone) have been granted to Qilu Pharmaceutical. The upfront payment is 380 million RMB, with subsequent sales milestones totaling up to 500 million RMB. Additionally, a royalty of "up to double-digit percentages of net sales" will be received.

AndCalico's Deal,According to the announcement by Mabwell, Calico will...Pay a one-time, non-refundable upfront payment of $25 millionMoreover, Mabwell can additionally obtainTotaling up to US$571 million at mostProximal, development, registration and commercialization milestone payments, as well as tiered royalties based on the net sales of the licensed products.

Mabwell Grants Calico Exclusive Rights to Develop, Manufacture, and Commercialize Licensed Products in All Regions Outside Greater China (Mainland China, Hong Kong, Macao, and Taiwan). Mabwell is entitled to receive an upfront payment, milestone payments, and tiered royalties based on the net sales of the licensed products.

This exclusive license agreement involves therapies targeting the cytokine IL-11 and discloses detailed information about a candidate drug named 9MW3811.

• 9MW3811It is a humanized monoclonal antibody independently developed by Mabwell that targets human interleukin-11 (IL-11). It can efficiently block the activation of downstream signaling pathways of IL-11 and inhibit the pathophysiological functions induced by IL-11.Thereby achieving therapeutic effects on fibrosis and tumors.。

• 9MW3811Approved for clinical trials in China, Australia, and the U.S., Phase I clinical studies in China and Australia have been completed.

MabwellThe official website also highlighted the potential of this monoclonal antibody in treating idiopathic pulmonary fibrosis.

Calico, a biotech company headquartered in California, was co-founded by Alphabet (Google's parent company) and industry heavyweight Dr. Arthur Levinson. The company aims to delve deeply into the biology of aging to help develop interventions that extend healthy lifespan.

Calico has established a series of partnerships, including collaborations with AbbVie, the Broad Institute of MIT and Harvard, and other institutions.